Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma
Ronkainen, Hanna; Hirvikoski, Pasi; Kauppila, Saila; Vuopala, Katri S; Paavonen, Timo; Selander, Katri (2011)
Ronkainen, Hanna
Hirvikoski, Pasi
Kauppila, Saila
Vuopala, Katri S
Paavonen, Timo
Selander, Katri
2011
Journal of Experimental & Clinical Cancer Research 30
84
Lääketieteen yksikkö - School of Medicine
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
Julkaisun pysyvä osoite on
https://urn.fi/urn:nbn:uta-3-498
https://urn.fi/urn:nbn:uta-3-498
Kuvaus
BMC
Tiivistelmä
Background
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We also evaluated the prognostic value of TLR9 in RCC.
Methods
TLR9 expression in RCC was characterized with immunohistochemistry in a retrospective study population of 152 RCC patients who underwent renal surgery. The TLR9 staining intensity was compared with clinical parameters.
Results
Of the studied tumours, 112 (81%) exhibited cytoplasmic TLR9 immunostaining. No association was detected between cytoplasmic TLR9 immunoexpression intensity and stage, nuclear grade, histological subtype or tumour necrosis. Cytoplasmic TLR9 immunoexpression was, however, a marker of favourable RCC specific survival both in univariate analysis and in multivariate regression model.
Conclusions
We conclude that TLR9 expression is an independent prognostic marker of RCC and the absence of TLR9 expression is related to poorer prognosis in RCC.
Keywords:
renal cell carcinoma; toll-like receptor 9; tumour necrosis; prognosis
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We also evaluated the prognostic value of TLR9 in RCC.
Methods
TLR9 expression in RCC was characterized with immunohistochemistry in a retrospective study population of 152 RCC patients who underwent renal surgery. The TLR9 staining intensity was compared with clinical parameters.
Results
Of the studied tumours, 112 (81%) exhibited cytoplasmic TLR9 immunostaining. No association was detected between cytoplasmic TLR9 immunoexpression intensity and stage, nuclear grade, histological subtype or tumour necrosis. Cytoplasmic TLR9 immunoexpression was, however, a marker of favourable RCC specific survival both in univariate analysis and in multivariate regression model.
Conclusions
We conclude that TLR9 expression is an independent prognostic marker of RCC and the absence of TLR9 expression is related to poorer prognosis in RCC.
Keywords:
renal cell carcinoma; toll-like receptor 9; tumour necrosis; prognosis
Kokoelmat
- Artikkelit [6140]